Advertisement
NVST vs UTMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVST is a StrongBuy and UTMD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVST’s FA Score shows that 1 FA rating(s) are green whileUTMD’s FA Score has 0 green FA rating(s).
- NVST’s FA Score: 1 green, 4 red.
- UTMD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVST’s TA Score shows that 4 TA indicator(s) are bullish while UTMD’s TA Score has 5 bullish TA indicator(s).
- NVST’s TA Score: 4 bullish, 4 bearish.
- UTMD’s TA Score: 5 bullish, 2 bearish.
Price Growth
NVST (@Pharmaceuticals: Other) experienced а +10.77% price change this week, while UTMD (@Pharmaceuticals: Other) price change was +2.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.67%. For the same industry, the average monthly price growth was +3.82%, and the average quarterly price growth was +6.03%.
Reported Earning Dates
NVST is expected to report earnings on Feb 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+2.67% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| NVST | UTMD | NVST / UTMD | |
| Capitalization | 3.44B | 181M | 1,899% |
| EBITDA | 341M | 15.6M | 2,186% |
| Gain YTD | 8.813 | -6.871 | -128% |
| P/E Ratio | 232.22 | 15.92 | 1,459% |
| Revenue | 2.62B | 38.8M | 6,758% |
| Total Cash | 1.13B | 82.2M | 1,380% |
| Total Debt | 1.6B | 256K | 625,781% |
NVST | UTMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 66 | |
PRICE GROWTH RATING 1..100 | 52 | 62 | |
P/E GROWTH RATING 1..100 | 4 | 37 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
UTMD's Valuation (34) in the Medical Specialties industry is somewhat better than the same rating for NVST (85) in the null industry. This means that UTMD’s stock grew somewhat faster than NVST’s over the last 12 months.
UTMD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVST (100) in the null industry. This means that UTMD’s stock grew similarly to NVST’s over the last 12 months.
UTMD's SMR Rating (66) in the Medical Specialties industry is in the same range as NVST (86) in the null industry. This means that UTMD’s stock grew similarly to NVST’s over the last 12 months.
NVST's Price Growth Rating (52) in the null industry is in the same range as UTMD (62) in the Medical Specialties industry. This means that NVST’s stock grew similarly to UTMD’s over the last 12 months.
NVST's P/E Growth Rating (4) in the null industry is somewhat better than the same rating for UTMD (37) in the Medical Specialties industry. This means that NVST’s stock grew somewhat faster than UTMD’s over the last 12 months.
| NVST | UTMD | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 50% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 61% |
| Momentum ODDS (%) | 3 days ago 65% | N/A |
| MACD ODDS (%) | 3 days ago 57% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 47% |
| Advances ODDS (%) | 4 days ago 63% | 4 days ago 53% |
| Declines ODDS (%) | 12 days ago 70% | 10 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 82% | 3 days ago 61% |
| Aroon ODDS (%) | 5 days ago 72% | 3 days ago 50% |
Advertisement
NVST and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVST has been closely correlated with XRAY. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVST jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | -0.29% | ||
| XRAY - NVST | 69% Closely correlated | +1.80% | ||
| ALGN - NVST | 58% Loosely correlated | -0.18% | ||
| AZTA - NVST | 57% Loosely correlated | -4.80% | ||
| BIO - NVST | 57% Loosely correlated | -1.56% | ||
| SOLV - NVST | 56% Loosely correlated | -0.58% | ||
More | ||||